Amit Munshi

Chief Executive Officer, Orna Therapeutics
Park City, Utah,United States
Find Amit Munshi's Email
Find Amit Munshi's Phone

Who Is Amit Munshi?

Total Experience40 years
CompanyOrna Therapeutics
CountryUnited States

Amit Munshi is a highly accomplished biopharmaceutical executive with over three decades of extensive experience in global drug development, commercialization, and corporate strategy. He is recognized as a strategic leader with a strong track record of building and leading high-growth life sciences companies. Throughout his career, Munshi has held numerous leadership positions, including CEO roles where he successfully executed company turnarounds, secured significant financing, and orchestrated major M&A deals. His expertise spans various therapeutic areas, with a recent focus on cutting-edge fields like RNA medicines and immunology. He is currently the President and CEO of ReNAgade Therapeutics, a company at the forefront of RNA technology.

How Did Amit Munshi's Career Path Shape Their Journey?

Amit Munshi's work history includes a series of influential roles in various companies. Here is a detailed list of his professional journey:

Orna Therapeutics - Chief Executive Officer(2024 to Present)
Zura Bio Limited (Nasdaq: ZURA) - Chairman(2023 to Present)
Enterprise Therapeutics - Chairman, Board of Directors(2020 to Present)
Galecto, Inc. - Member Board Of Directors(2020 to Present)
Oxeia Biopharmaceuticals - Co-Founder(2014 to Present)
ReNAgade Therapeutics - Chief Executive Officer & President (2023 to 2024)
Arena Pharmaceuticals, Inc. - President and Chief Executive Officer(2016 to 2022)
Pulmatrix Inc. - Board Member(2017 to 2021)
Cytrellis Biosystems, Inc. - Board Member(2016 to 2019)
Epirus Biopharmaceuticals, Inc - President and CEO(2012 to 2016)

What Are Amit Munshi's Key Achievements?

Led Arena Pharmaceuticals to $6.7B Pfizer Acquisition

As President and CEO of Arena Pharmaceuticals, Amit Munshi orchestrated a remarkable corporate turnaround. He strategically refocused the company's R&D pipeline on high-potential assets in immunology and cardiovascular disease, significantly increasing its value and culminating in a landmark $6.7 billion all-cash acquisition by Pfizer in 2022.

Pioneering Leadership in RNA Therapeutics

Currently serves as the President and CEO of ReNAgade Therapeutics, placing him at the vanguard of RNA medicine innovation. He leads the company's mission to develop a comprehensive RNA platform that integrates delivery, coding, editing, and gene insertion capabilities to treat diseases on a global scale.

Successful Commercialization of KYBELLA®

While serving as President and CEO of Kythera Biopharmaceuticals, he was instrumental in the commercial readiness and successful launch of KYBELLA®, the first-in-class, FDA-approved injectable drug for submental fullness. His leadership contributed to the company's eventual acquisition by Allergan for $2.1 billion.

Extensive Global Commercial Experience

Throughout his tenure at major pharmaceutical companies like Amgen, AstraZeneca, and Chiron, he held key commercial leadership roles, driving the growth and market success of numerous blockbuster products across multiple continents.

What's Amit Munshi's Educational Background?

MBA

Claremont Graduate University - Peter F. Drucker and Masatoshi Ito Graduate School of Management - Year 1991

BA, BS, History, Economics

University of California, Riverside - Year 1986

Buying Intent Signals for Amit Munshi

Highperformr Signals uncover buying intent and give you clear insights to target the right people at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance

Company Overview

Orna Therapeutics
Total employees150
HeadquartersCambridge
Founded2019

Orna Therapeutics is a biotechnology company pioneering a new class of fully engineered circular RNA (oRNAâ„¢) therapies. Unlike traditional linear mRNA, Orna's circular RNA is designed to be more stable and produce larger quantities of therapeutic proteins, potentially leading to more effective treatments. The company's platform focuses on developing groundbreaking therapies for a range of diseases, with initial programs in cancer, including in situ CAR (isCAR) therapies, and genetic disorders.

Orna Therapeutics Funding Information
$321M - Total Funding Raised
$221M - Most recent funding amount
3 - Number of funding rounds
Aug 16, 2022 - Latest funding round
Lead Investors:
MPM Capital
BioImpact Capital
Merck
Bristol Myers Squibb
Astellas Venture Management
Novartis Institutes for BioMedical Research
Kite, a Gilead Company

Highperformr's free tools for company research

Find contact info

Get verified emails, phone numbers, and LinkedIn profile details

Find similar contacts

Discover contacts with similar roles, seniority, or companies

Perform deep contact research

Uncover insights like skills, work history, social links, and more

Discover, research and enrich contacts with Highperformr — Smarter, Faster

Explore contacts in-depth — from verified emails and phone numbers to LinkedIn activity, job changes, and more — all in one powerful view.

Highperformr AI helps you surface the right people and enrich your CRM with live, accurate contact insights so your teams can connect faster and close smarter.

  • Track signals like job change, promotion, and LinkedIn activity
  • Enrich contacts with verified email, phone, and social data instantly
  • Automate enrichment and updates with powerful workflows
  • Sync enriched contact info directly into your CRM and tools

Thousands of contacts — including decision-makers, influencers, and ICP matches — are just a search away.

Thousands of companies, including, are just a search away.